Cas-CLOVER’s Key Advantages In Animal Model Gene Editing
In this article we discuss our proof-of-concept (POC) data in [...]
Hera Biolabs Receives AAALAC Accreditation For Exceptional Animal Care
One of the most important parts of the entire drug [...]
Fine Needle Aspirate Serial Tumor Sampling Services To Boost Your Xenograft Study Capabilities
Xenograft tumors from human cancer cell lines in immunocompromised mice are [...]
Validation Of The SRG Rat For Human Tumor Studies Published In PLOS ONE
We Are Excited To Announce That A Validation Study Using [...]
Gene Editing With piggyBac: Creating A Curative Treatment For Beta-Thalassemia
Genetic Engineering Can Soon Lead To Lifelong Cures For Diseases [...]
Humanized Skin And Immune Cell Rodent Models Revolutionizing Scientific Research
A current challenge in medical research is developing and choosing [...]
OncoRat® Featured In Clinical Cancer Research For Prostate Cancer Studies
Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems: A Case [...]
The OncoRat® Is The Ideal Host For Patient-Derived Xenografts Of Ovarian Cancer Cells
Ovarian cancer is the most lethal gynecological cancer in the [...]
H358 NSCLC Xenografts In Humanized Rats: The Ideal In Vivo Model For Studying KRAS Mutations
Lung adenocarcinomas, the major histological subtype of non-small cell lung [...]
Hera Biolabs Announces Molecular Cancer Therapeutics Publication On Immunodeficient Rats For Oncology Research
Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics, entitled, "Sprague Dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts."